Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

ENCINITAS, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that Company executives will provide a company overview during fireside chats at the following upcoming investor conferences:

  • Event: Credit Suisse 31st Annual Healthcare Conference
    Location: Rancho Palos Verdes, CA
    Date: Wednesday, November 9, 2022
    Time: 12:50-1:20 PM PT / 3:50-4:20 PM ET
  • Event: Stifel 2022 Healthcare Conference
    Location: New York, NY
    Date: Tuesday, November 15, 2022
    Time: 3:00-3:30 PM ET
  • Event: Jefferies London Healthcare Conference
    Location: London, United Kingdom
    Date: Thursday, November 17, 2022
    Time: 8:35-9:05 AM GMT / 3:35-4:05 AM ET

Members of the Ventyx management team will also host investor meetings during the conferences.

Webcasts of the presentations will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this website shortly after conclusion of each event for thirty days.

About Ventyx Biosciences

Ventyx is a clinical-stage biopharmaceutical company focused on developing innovative oral medicines for patients living with autoimmune and inflammatory disorders. We believe our ability to efficiently discover and develop differentiated drug candidates will allow us to address important unmet medical need with novel oral therapies that can shift immunology markets from injectable to oral drugs. Our current pipeline includes three clinical-stage internally discovered programs targeting TYK2, S1P1R and NLRP3, positioning us to become a leader in the development of oral immunology therapies. Ventyx is headquartered in Encinitas, California.

Investor Relations Contact
Patti Bank
Managing Director
ICR Westwicke
(415) 513-1284
IR@ventyxbio.com

Staff

Recent Posts

CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD

SAN DIEGO, CA / ACCESS Newswire / December 22, 2025 / CV Sciences, Inc. (OTCQB:CVSI)…

2 hours ago

Private Wellness Club Continuum Unlocks Final Membership Tier at West Village Flagship

The New Year Introduces Continuum's Entry-Level Tier, Starting at $25,000 Per YearNEW YORK, Dec. 22,…

5 hours ago

Ginkgo Bioworks Partners with Carnegie-Mellon University to Develop Innovative New Cancer Screening Approach

BOSTON, Dec. 22, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced its partnership with…

5 hours ago

KLAS Report Shows Strong Early Results for TrustCommerce Cloud Payments

CHICAGO, Dec. 22, 2025 /PRNewswire/ -- TrustCommerce®, a Sphere company and leading provider of end-to-end…

5 hours ago

BioFlorida Announces Appointment of Dr. Anthony Japour, CEO of iTolerance, Inc., as Chair of the Southeast Chapter

MIAMI, Dec. 22, 2025 /PRNewswire/ -- BioFlorida, Inc. ("BioFlorida"), Florida's preeminent life sciences association, is…

5 hours ago

Truemed Closes $34 Million Series A To Unlock HSA/FSA Funds For Lifestyle Interventions

Andreessen Horowitz leads the funding round which will accelerate the company's leadingtelehealth marketplaceAUSTIN, Texas, Dec.…

5 hours ago